Poor
Mostly Unaligned
Patient Risk:
Medium
Summary
The response contains multiple claims not supported by the provided FDA label excerpts (e.g., Nordimet branding/equivalence, cancer/high-dose use, generic/patent/interchangeability details, and injections). While several safety/monitoring concepts are supported (liver, lungs, blood counts, pregnancy risk, renal impairment monitoring/modification), the unsupported claims substantially reduce overall label alignment.
Category Scores
Accurate Statements
Methotrexate can affect the liver.
Supported: TREXALL can cause severe/potentially irreversible hepatotoxicity; monitor liver tests (5.5 Hepatotoxicity).
Methotrexate can affect the lungs.
Supported: pulmonary toxicity including interstitial pneumonitis; monitor and withhold/discontinue (5.6 Pulmonary Toxicity).
Methotrexate can affect blood counts.
Supported: TREXALL suppresses hematopoiesis; can cause pancytopenia/cytopenias; obtain blood counts (5.3 Myelosuppression).
Clinicians typically monitor blood counts and liver function when using methotrexate.
Supported: obtain blood counts at baseline/periodically/as indicated (5.3); monitor liver tests at baseline/periodically/as indicated (5.5).
Clinicians adjust methotrexate dosing for factors like kidney function.
Supported: renal impairment reduces elimination; closely monitor; reduce dosage or discontinue as appropriate (8.6); renal toxicity and dosage modification language (5.8, 2.6).
Methotrexate is harmful in pregnancy.
Partially supported: label states embryo-fetal toxicity/fetal death risk and contraindication in pregnant women with non-neoplastic diseases (8.1 Pregnancy).
Unsupported Statements
Nordimet is a brand name for methotrexate.
The provided label excerpts contain no mention of Nordimet or any brand-to-ingredient mapping.
Nordimet refers to a specific marketed methotrexate product (brand/formulation).
Nordimet is not mentioned in the provided label excerpts.
The active ingredient in Nordimet is methotrexate.
No Nordimet product/composition information is provided in the label excerpts.
Methotrexate is used in low doses for inflammatory and autoimmune diseases.
Label excerpts provide indications for rheumatoid arthritis and severe psoriasis but do not support the characterization as 'low doses' or 'inflammatory and autoimmune diseases' broadly.
Methotrexate is used in low doses most commonly for rheumatoid arthritis and psoriasis.
Label excerpts support rheumatoid arthritis and severe psoriasis, but do not state 'low doses' or 'most commonly.'
Methotrexate is used in higher doses for some cancers, depending on the indication and formulation.
The provided label excerpts do not include cancer indications or any statement about higher-dose cancer use.
Methotrexate can be taken by different routes.
The provided label excerpts reference 'route of administration' and oral absorption, but do not explicitly support that patients can take methotrexate by different routes.
Methotrexate is commonly taken as oral tablets and injections.
The provided label excerpts describe TREXALL as tablets for oral use and do not mention injections or common route patterns.
Nordimet may correspond to a particular presentation or route.
Nordimet/presentation/route link is not described in the provided label excerpts.
The route/presentation of Nordimet affects how patients take it.
No Nordimet-specific route/presentation information is provided in the label excerpts.
The route/presentation of Nordimet affects how dosing instructions are written by the prescriber.
No Nordimet-specific dosing-instruction-by-presentation information is provided in the label excerpts.
Brand-name methotrexate products can have generics.
No information on generics/interchangeability is included in the provided label excerpts.
Interchangeable versions of methotrexate may be available depending on jurisdiction, strength, and formulation.
No information on interchangeability, jurisdiction, or regulatory availability is included in the provided label excerpts.
Patent and exclusivity status for methotrexate products varies by country.
No patent/exclusivity information is included in the provided label excerpts.
Patent and exclusivity status for methotrexate products varies by which specific methotrexate presentation is being sold.
No patent/exclusivity information and no linkage to presentation is included in the provided label excerpts.
Contradictions
Important Omissions
The dosing administration specifics required by the label (e.g., once-weekly regimen and medication error prevention instructions) are not addressed in the extracted claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several unsupported claims concern product identity (Nordimet), route/injection use, and major dosing context (cancer/high-dose), which could mislead about appropriate use. Some safety-related monitoring concepts are supported by the label excerpts (blood counts, liver tests, pulmonary/hepatotoxicity), but overall alignment is insufficient.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Multiple substantive claims are not supported by the provided FDA label excerpts, especially Nordimet brand equivalence, cancer/high-dose use, and injection/route availability and generic/patent/interchangeability details.
Suggested Improvement
Restrict claims to those explicitly supported by the provided label text (e.g., TREXALL indications for rheumatoid arthritis and severe psoriasis; pregnancy embryo-fetal risk/contraindication in non-neoplastic disease; hepatotoxicity/pulmonary toxicity/myelosuppression monitoring; renal impairment reduced elimination and dosage reduction/discontinuation). Remove Nordimet-specific and general market/regulatory interchangeability/patent statements unless present in the label excerpts.